MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
MyoKardia Second Quarter 2018 Financial Results (Replay)
August 08, 2018 at 4:30 p.m. ET
MyoKardia Inc at the 2018 Wedbush Pacgrow Healthcare Conference (Replay)
August 14, 2018 at 10:55 a.m. ET
Recent Press Releases
NASDAQ GS | MYOK (Common Stock)
$55.90 - 0.55
08/15/182:46 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.